Full-Time

Scientist – Antibody Discovery & Characterization

Posted on 10/2/2025

Ginkgo Bioworks

Ginkgo Bioworks

501-1,000 employees

Designs, grows custom organisms for products

No salary listed

Boston, MA, USA

Hybrid

On-site 3 days per week at Boston Seaport headquarters.

Category
Biology & Biotech (5)
, , , ,
Requirements
  • Ph.D. in Biochemistry, Immunology, Bioengineering, or a related field with 0-2 years of industry/academic experience (or M.S. with 6+ years or B.S. with 8+ years of relevant experience)
  • Deep expertise in the design, engineering, expression, and characterization of complex protein formats, with a demonstrated track record working with bispecific or multi-specific antibodies.
  • Demonstrated proficiency in antibody developability assessment using multiple biophysical techniques (e.g., DSF, DLS, SEC, HIC, AC-SINS, Polyreactivity).
  • Extensive hands-on expertise with SPR (e.g., Biacore) or BLI (e.g., Octet) for quantitative analysis of complex binding interactions, such as simultaneous binding of bispecifics.
  • Proven ability to independently lead projects and contribute to experimental design.
  • Excellent communication skills and the ability to thrive in a highly collaborative, multidisciplinary environment.
Responsibilities
  • Lead the design and engineering of novel antibody formats, including bispecific and multi-specific constructs, to optimize for function and developability.
  • Develop and execute workflows for the production (transfection, expression) and purification of complex antibody formats.
  • Design and implement a wide range of biophysical and functional assays to evaluate antibody binding, stability, and activity, with a focus on challenges unique to bi/multi-specifics, VHHs, and scFvs.
  • Develop methods for developability assessments for novel antibody formats (such as bi/multi-specifics), as well as binding kinetics (SPR/BLI), and functional cell-based assays.
  • Provide technical leadership and hands-on expertise to troubleshoot expression, purification, and analytical challenges associated with novel formats.
  • Contribute to scientific strategy, innovation, and the continuous improvement of our developability assessment platform.
  • Mentor and guide junior scientists.
  • Author technical reports, SOPs, and present findings to internal leadership and external customers.
Desired Qualifications
  • Industry experience in therapeutic antibody discovery and development.
  • Experience with or exposure to computational tools for antibody discovery, including the use of AI/ML models for in silico developability prediction or sequence optimization.
  • Familiarity with high-throughput expression, purification, and screening techniques.
  • Knowledge of antibody display platforms (e.g., phage, yeast) or other discovery methods is desirable.

Ginkgo Bioworks designs and grows custom organisms using a cell-programming platform to produce ingredients and therapeutics across industries. It programs cells to make specific compounds and then optimizes and scales the production with partner companies. Unlike firms that sell one product, it collaborates with many clients to develop customized biological solutions. Its goal is to turn biological design into real-world, scalable products across multiple sectors.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2009

Simplify Jobs

Simplify's Take

What believers are saying

  • OpenAI GPT-5 collaboration cuts protein synthesis costs 40% across 36,000 experiments.
  • Bioworks7 expands capacity for biopharma and mammalian therapeutics programming.
  • ARPA-H PREDICTS and EMBODY fund RNA designs and datasets for drug safety and CAR therapies.

What critics are saying

  • Q1 2026 revenue falls 49% to $19M as cell engineering declines 26% yearly.
  • $125-150M 2026 cash burn drains $474M reserves, forcing dilutive financing by mid-2027.
  • BTIG cuts target to $5 doubting Nebula autonomous lab monetization post-biosecurity divestiture.

What makes Ginkgo Bioworks unique

  • Ginkgo engineers custom organisms via Design-Build-Test-Learn platform for partners.
  • Reconfigurable Automation Carts enable modular, scalable end-to-end biological workflows.
  • Ginkgo Cloud Lab offers AI-driven EstiMate for natural language experiment submission.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited paid time off

Comprehensive health and parental leave benefits

Flexible work options

Commuter benefits

State-of-the-art labs, work spaces, and conference rooms

Competitive 401K contribution

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

2%

2 year growth

7%
Yahoo Finance
Mar 15th, 2026
Ginkgo Bioworks price targets cut as analysts split on automation lab rollout and cash burn

Analysts have trimmed price targets on Ginkgo Bioworks, with bullish views dropping to $12 from $14 and bearish targets falling to $5 from $9. The revisions reflect mixed sentiment around execution risk and recent business changes. TD Cowen maintained a Buy rating at $12, citing multi-year growth frameworks and improving investor sentiment ahead of 2026 guidance updates. BTIG kept its Sell rating at $5, noting it wants better visibility into how Ginkgo will monetise autonomous labs following the biosecurity business divestiture. Ginkgo recently launched Ginkgo Cloud Lab, a browser-based platform for running benchwork on autonomous lab infrastructure. The company announced collaborations with OpenAI on GPT-5-based biological experiments and with Invaio Sciences on microbial strains for crop protection.

PR Newswire
Mar 2nd, 2026
Ginkgo Bioworks launches cloud lab with AI-powered autonomous infrastructure

Ginkgo Bioworks has launched Ginkgo Cloud Lab, a web-based interface allowing researchers to access the company's autonomous laboratory infrastructure remotely. The platform runs on proprietary Reconfigurable Automation Carts, which combine robotic arms, maglev sample transport and industrial software. The Cloud Lab provides access to over 70 instruments covering biological operations including sample preparation, liquid handling and analytical readouts. Its AI-driven agent, EstiMate, enables scientists to submit protocols in natural language and receive immediate compatibility assessments and pricing. The launch supports Ginkgo's 2026 strategy to transition all R&D services to Nebula, its autonomous lab in Boston, and phase out traditional laboratory benches. The company is inviting researchers from academia and biopharmaceutical firms to test the platform at cloud.ginkgo.bio.

Yahoo Finance
Mar 1st, 2026
Ginkgo Bioworks falls 30% despite Invaio peptide crop protection collaboration and $250M cost savings

Ginkgo Bioworks has reported full-year 2025 results showing lower revenue at $170.16 million and a reduced net loss of $312.76 million, alongside announcing a collaboration with Invaio Sciences on peptide-based crop protection. Despite this, shares declined 30.48% in one day to $6.75. The biotech company has achieved $250 million in annual cost savings and maintains a strong balance sheet with $474 million in cash and no bank debt. Analyst estimates suggest the stock is 32.5% undervalued, with a fair value of $10 per share. However, the company faces significant headwinds, with shares down 22.41% year-to-date and 87.86% over three years. Key risks include slower adoption of its AI and automation platform and margin pressure from underutilised laboratory capacity.

Yahoo Finance
Feb 28th, 2026
Ginkgo Bioworks pivots to autonomous labs, plans biosecurity spin-off amid revenue decline

Ginkgo Bioworks has outlined a 2026 strategy centred on autonomous labs, whilst reporting declining cell engineering revenue and improved cash burn. The company will concentrate capital on its Nebula system in Boston, expand capacity towards 100 racks, and commercialise offerings including Solutions, Datapoints and cloud lab services integrated with AI. Cell engineering revenue fell 26% year-on-year in Q4, with full-year revenue of $133 million versus $174 million in 2024. However, R&D and G&A cuts improved losses, reducing cash burn to $171 million for 2025. Management is guiding cash burn of $125–$150 million for 2026. The company plans to spin off its biosecurity business to outside investors whilst retaining a minority stake, freeing capital for autonomous lab investments.

PR Newswire
Feb 26th, 2026
Ginkgo Bioworks shifts focus to autonomous labs, divests biosecurity business

Ginkgo Bioworks reported fourth quarter 2025 total revenue of $33 million, down 24% from the prior year, with a GAAP net loss of $81 million. Full year revenue reached $170 million, down 25% from 2024, with adjusted EBITDA improving to negative $167 million from negative $293 million. The synthetic biology company announced it will divest its biosecurity business to a consortium of investors in exchange for a minority equity stake, with the transaction expected to close in the first half of 2026. CEO Jason Kelly said Ginkgo will now focus investment on autonomous laboratory offerings. Ginkgo is expanding its Boston autonomous lab to include over 100 robotic automated cells by year-end and recently completed a collaboration with OpenAI achieving a 40% improvement in cell-free protein synthesis. The company ended 2025 with $423 million in cash and expects total cash burn of $125-150 million in 2026.

INACTIVE